Identifying molecular markers for aggressive pituitary tumors
Official title: Molecular biomarkers of future aggressive behavior in pituitary tumors
Funded at Sloan-Kettering Inst Can Research · NIH-10821436 · Data updated 2026-11-12
This study is looking at the genetic changes in aggressive pituitary tumors that grow quickly after treatment, to help doctors find markers that can predict how these tumors will behave and improve treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 15, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $196,525 |
| NIH project number | 5R21CA280469-02 |
| Project ID | NIH-10821436 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pituitary adenomas who are at risk of aggressive tumor behavior.
✕Less likely to help
Patients with non-aggressive pituitary tumors or those who do not have pituitary adenomas may not benefit from this research.
What this research studies
This research investigates the genetic and epigenetic changes in pituitary adenomas that exhibit aggressive behavior, which is characterized by rapid growth after treatment. The study aims to identify specific molecular biomarkers that can predict the likelihood of these tumors becoming more aggressive, thereby helping clinicians make better treatment decisions. By analyzing patterns of chromosome variations and alterations in genes associated with tumor aggression, the research seeks to establish a foundation for improved patient management and clinical trial development.
Why it matters
Potential benefit: If successful, this research could lead to better identification and treatment strategies for patients with aggressive pituitary tumors, ultimately improving their outcomes.
How similar studies have gone: While research on pituitary tumors is limited, similar approaches in identifying biomarkers for other aggressive cancers have shown promise, suggesting potential for success in this area.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Lin, Andrew — Sloan-Kettering Inst Can Research
- Study coordinator: Lin, Andrew
Related research
Other NIH-funded projects on the same topics.
-
Understand how skeletal muscle nuclei specialize and arrange themselves for proper muscle function
A study to uncover how the hundreds of nuclei in skeletal muscle fibers acquire different roles and positions to keep muscles strong and healthy.
-
Genomic profiling and outcomes of cancers in World Trade Center-exposed survivors and responders
This project looks at the genetic makeup and real-world cancer outcomes in people exposed to the World Trade Center disaster to understand how their cancers behave and respond to treatments.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
High-specificity genome-scale cell-surface proteomics to find tumor targets
A cancer research project is trying to map all the proteins on the surface of ultra-rare sarcoma cells to find safe, targeted ways to treat them.
-
Priorities for testing and choosing combination therapies in rhabdoid tumors to guide clinical trials
A coordinated, multi-site effort will rigorously test promising drug combinations in rhabdoid tumors to identify the most promising options for future patient trials.
-
ecDNA in Cancer: Understanding and targeting circular DNA that drives tumor growth
A cancer-focused project to understand how extrachromosomal DNA helps tumors grow and resist treatment, and to develop new ways to target these mechanisms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.